-
公开(公告)号：US07759336B2
公开(公告)日：2010-07-20
申请号：US10538758
申请日：2003-12-09
IPC分类号： A01N43/00 , A61K31/55 , C07D223/00
CPC分类号： C07D221/22 , C07D239/48 , C07D239/95 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D493/10
摘要： The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)
摘要翻译： 由式（I）和（II）表示的化合物，其盐，其N-氧化物或其溶剂合物或其前药及其药物组合物具有CXCR4调节作用，并且它们在治疗中有效 预防各种炎症性疾病，各种过敏性疾病，人类免疫缺陷病毒的获得性免疫缺陷综合征感染或再生治疗药物。 （其中环A表示可以具有取代基的含氮杂环基;环B表示可以具有取代基的杂环基或可以具有取代基的杂环基; Y表示 可以具有取代基的烃基，可以具有取代基的杂环基，可被保护的氨基，可被保护的羟基或可被保护的巯基; T代表 环A或可被保护的氨基。）
-
公开(公告)号：US08153625B2
公开(公告)日：2012-04-10
申请号：US12776989
申请日：2010-05-10
IPC分类号： A61K31/55 , C07D403/00
CPC分类号： C07D221/22 , C07D239/48 , C07D239/95 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D493/10
摘要： The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.).
摘要翻译： 由式（I）和（II）表示的化合物，其盐，其N-氧化物或其溶剂合物或其前药及其药物组合物具有CXCR4调节作用，并且它们在治疗中有效 预防各种炎症性疾病，各种过敏性疾病，人类免疫缺陷病毒的获得性免疫缺陷综合征感染或再生治疗药物。 （其中环A表示可以具有取代基的含氮杂环基;环B表示可以具有取代基的杂环基或可以具有取代基的杂环基; Y表示 可以具有取代基的烃基，可以具有取代基的杂环基，可被保护的氨基，可被保护的羟基或可被保护的巯基; T代表 环A或可被保护的氨基。
-
公开(公告)号：US20070167459A1
公开(公告)日：2007-07-19
申请号：US10538758
申请日：2003-12-09
IPC分类号： A61K31/519 , A61K31/517 , C07D403/02
CPC分类号： C07D221/22 , C07D239/48 , C07D239/95 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D493/10
摘要： The compound represented by formulae (I) and (II), the salt thereof, the N-oxide thereof or the solvate thereof, or the prodrug thereof and the pharmaceutical composition comprising thereof have a CXCR4-regulating effect, and they are effective in treatment and prevention of various inflammatory disease, various allergic disease, acquired immunodeficiency syndrome infection with human immunodeficiency virus, or agents for regeneration therapy. (wherein ring A represents a nitrogen-containing heterocyclic group which may have a substituent(s); ring B represents a homocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s); and Y represents a hydrocarbon group which may have a substituent(s), a heterocyclic group which may have a substituent(s), an amino group which may be protected, a hydroxyl group which may be protected or a mercapto group which may be protected; T represents ring A or an amino group which may be protected.)
摘要翻译： 由式（I）和（II）表示的化合物，其盐，其N-氧化物或其溶剂合物或其前药及其药物组合物具有CXCR4调节作用，并且它们在治疗中有效 预防各种炎症性疾病，各种过敏性疾病，人类免疫缺陷病毒的获得性免疫缺陷综合征感染或再生治疗药物。 （其中环A表示可以具有取代基的含氮杂环基;环B表示可以具有取代基的杂环基或可以具有取代基的杂环基; Y表示 可以具有取代基的烃基，可以具有取代基的杂环基，可被保护的氨基，可被保护的羟基或可被保护的巯基; T代表 环A或可被保护的氨基。）
-
公开(公告)号：US20060004010A1
公开(公告)日：2006-01-05
申请号：US10520660
申请日：2003-07-08
申请人： Hiromu Habashita , Masaya Kokubo , Shiro Shibayama , Hideaki Tada , Kenji Sagawa
发明人： Hiromu Habashita , Masaya Kokubo , Shiro Shibayama , Hideaki Tada , Kenji Sagawa
IPC分类号： A61K31/498 , C07D43/14
CPC分类号： C07D409/12 , A61K31/4965 , A61K31/497 , A61K31/498 , A61K31/506 , A61K31/55 , C07D241/22 , C07D241/26 , C07D241/44 , C07D401/12
摘要： A compound of formula (I) or a salt thereof, and medical use thereof (the symbols in the formula are as described in the specification). The compound of formula (I) has CCR4 antagonistic activity, and therefore is useful as a preventive and/or therapeutic agent for diseases associated with CCR4, i.e., CCR4-mediated diseases such as inflammatory and/or allergic diseases [e.g., systemic inflammatory response syndrome (SIRS), anaphylaxis or anaphylaxis-like reaction, allergic vasculitis, reject reaction for graft organ, hepatitis, nephritis, nephrosis, pancreatitis, rhinitis, arthritis, inflammatory ocular diseases, inflammatory bowel diseases, diseases in cerebro and/or circulatory system, respiratory diseases, dermatic diseases, autoimmune diseases, etc.], and the like.
摘要翻译： 式（I）化合物或其盐及其医疗用途（式中的符号如说明书中所述）。 式（I）化合物具有CCR4拮抗活性，因此可用作与CCR4相关的疾病的预防和/或治疗剂，即CCR4介导的疾病如炎性和/或过敏性疾病[例如全身炎症反应 综合征（SIRS），过敏反应或过敏反应，过敏性血管炎，移植器官排斥反应，肝炎，肾炎，肾病，胰腺炎，鼻炎，关节炎，炎性眼部疾病，炎性肠病，脑脊液和/或循环系统疾病， 呼吸系统疾病，皮肤病，自身免疫性疾病等]等。
-
公开(公告)号：US20080009056A1
公开(公告)日：2008-01-10
申请号：US11703200
申请日：2007-02-07
摘要： A new polypeptide prepared from human library by the SST method and a process for preparation of it; a cDNA encoding the polypeptide; a fragment selectively hybridizing with the sequence of the cDNA; a replication or expression plasmid containing the cDNA integrated thereinto; a host cell transformed with plasmid; an antibody against the polypeptide; and a pharmaceutical composition containing the polypeptide or the antibody.
摘要翻译： 通过SST方法从人类文库制备的新多肽及其制备方法; 编码该多肽的cDNA; 选择性地与cDNA序列杂交的片段; 包含其中整合的cDNA的复制或表达质粒; 用质粒转化的宿主细胞; 抗多肽的抗体; 和含有多肽或抗体的药物组合物。
-
公开(公告)号：US06664383B1
公开(公告)日：2003-12-16
申请号：US09700397
申请日：2000-11-14
IPC分类号： C12Q168
CPC分类号： C07K14/4702 , A61K38/00 , C07K14/47 , C12N9/6421
摘要： A new human polypeptide, a cDNA encoding the same and a pharmaceutical use of it. The polypeptides of the present invention possess hematopoiesis regulating activity, tissue generation/regeneration activity, activin/inhibin activity, chemotactic/chemokinetic activity, hemostatic and thrombolytic activity, and receptor/ligand activity, therefore, they are expected to be useful for prevention and/or treatment of various diseases.
摘要翻译： 新的人多肽，编码它的cDNA及其药学用途。本发明的多肽具有造血调节活性，组织产生/再生活性，激活素/抑制素活性，趋化性/动力学活性，止血和溶栓活性，以及 受体/配体活性，因此预期它们可用于预防和/或治疗各种疾病。
-
7.发明申请Antagonist and agonist which bind to a strong binding site of chemokine receptor 审中-公开拮抗剂和激动剂，其结合趋化因子受体的强结合位点公开(公告)号：US20060251651A1
公开(公告)日：2006-11-09
申请号：US10538364
申请日：2003-12-12
申请人： Shiro Shibayama , Kenji Sagawa , Noriki Watanabe , Kazuhiko Takeda , Hideaki Tada , Daikichi Fukushima
发明人： Shiro Shibayama , Kenji Sagawa , Noriki Watanabe , Kazuhiko Takeda , Hideaki Tada , Daikichi Fukushima
IPC分类号： A61K39/395 , G01N33/567 , C07K16/28
CPC分类号： A61K31/49 , A61K31/00 , A61K31/503 , A61K31/5377 , G01N2333/715 , G01N2500/04
摘要： An antagonist or an agonist which binds to a strong binding site of CCR5; a preventive and/or therapeutic agent for an allergic disease, an inflammatory disease, an immune disease and/or a cancer which comprises the same; a method for screening a compound which binds to a strong binding site of CCR5; a preventive and/or therapeutic agent for an allergic disease, an inflammatory disease, an immune disease and/or a cancer which comprises the antagonist or the agonist selected by the screening method; an antagonist or an agonist which binds to a strong binding site of a chemokine receptor; a preventive and/or therapeutic agent for an allergic disease, an inflammatory disease, an immune disease and/or a cancer which comprises the same; a method for screening a compound which binds to a strong binding site of a chemokine receptor; and a preventive and/or therapeutic agent for an allergic disease, an inflammatory disease, an immune disease and/or a cancer which comprises the antagonist or the agonist selected by the screening method. The antagonist or the agonist of the present invention is useful as a preventive and/or therapeutic agent for an allergic disease, an inflammatory disease, an immune disease and/or a cancer.
摘要翻译： 结合CCR5的强结合位点的拮抗剂或激动剂; 用于过敏性疾病，炎性疾病，免疫疾病和/或包含该疾病的癌症的预防和/或治疗剂; 用于筛选结合CCR5的强结合位点的化合物的方法; 包含通过筛选方法选择的拮抗剂或激动剂的过敏性疾病，炎性疾病，免疫疾病和/或癌症的预防和/或治疗剂; 结合趋化因子受体的强结合位点的拮抗剂或激动剂; 用于过敏性疾病，炎性疾病，免疫疾病和/或包含该疾病的癌症的预防和/或治疗剂; 用于筛选结合趋化因子受体的强结合位点的化合物的方法; 以及包含通过筛选方法选择的拮抗剂或激动剂的过敏性疾病，炎性疾病，免疫疾病和/或癌症的预防和/或治疗剂。 本发明的拮抗剂或激动剂可用作过敏性疾病，炎性疾病，免疫疾病和/或癌症的预防和/或治疗剂。
-
公开(公告)号：US07638281B2
公开(公告)日：2009-12-29
申请号：US11703200
申请日：2007-02-07
摘要： A new polypeptide prepared from human library by the SST method and a process for preparation of it; a cDNA encoding the polypeptide; a fragment selectively hybridizing with the sequence of the cDNA; a replication or expression plasmid containing the cDNA integrated thereinto; a host cell transformed with plasmid; an antibody against the polypeptide; and a pharmaceutical composition containing the polypeptide or the antibody.
摘要翻译： 通过SST方法从人类文库制备的新多肽及其制备方法; 编码该多肽的cDNA; 选择性地与cDNA序列杂交的片段; 包含其中整合的cDNA的复制或表达质粒; 用质粒转化的宿主细胞; 抗多肽的抗体; 和含有多肽或抗体的药物组合物。
-
公开(公告)号：US07189546B2
公开(公告)日：2007-03-13
申请号：US10414378
申请日：2003-04-16
摘要： A new polypeptide prepared from human library by the SST method and a process for preparation of it; a cDNA encoding the polypeptide; a fragment selectively hybridizing with the sequence of the cDNA; a replication or expression plasmid containing the cDNA integrated thereinto; a host cell transformed with plasmid; an antibody against the polypeptide; and a pharmaceutical composition containing the polypeptide or the antibody.
摘要翻译： 通过SST方法从人类文库制备的新多肽及其制备方法; 编码该多肽的cDNA; 选择性地与cDNA序列杂交的片段; 包含其中整合的cDNA的复制或表达质粒; 用质粒转化的宿主细胞; 抗多肽的抗体; 和含有多肽或抗体的药物组合物。
-
公开(公告)号：US20100285527A1
公开(公告)日：2010-11-11
申请号：US12772617
申请日：2010-05-03
CPC分类号： C07K14/705 , A61K38/00 , C07K14/4703
摘要： Novel polypeptides produced by a human adult brain tissue, a cell line derived therefrom, a cell line derived from human bone marrow and a human umbilical cord venous endothelial cell line; a process for producing these polypeptides; cDNAs encoding the polypeptides; fragments hybridizable selectively with the cDNA sequences; replication or expression plasmids having the cDNAs integrated thereinto; host cells transformed by the plasmids; antibodies against the above polypeptides; and medicinal compositions containing the peptides or the antibodies.
摘要翻译： 由人成人脑组织产生的新型多肽，源自其的细胞系，源自人骨髓的细胞系和人脐带静脉内皮细胞系; 一种生产这些多肽的方法; 编码多肽的cDNA; 片段可与cDNA序列选择性杂交; 具有整合cDNA的复制或表达质粒; 由质粒转化的宿主细胞; 针对上述多肽的抗体; 以及含有肽或抗体的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.049 秒)
